Teprotumumab

證據等級: L5

預測適應症: 10 個

Teprotumumab: From Thyroid Eye Disease to Monosomy X

One-Sentence Summary

Teprotumumab is an anti-IGF-1R monoclonal antibody whose established use (referenced in the evidence pack's mechanistic rationale) is thyroid eye disease; formal original-indication data was not returned by this query. The TxGNN model's top prediction is Monosomy X (Turner syndrome karyotype) with a 99.79% score, but this candidate is supported by 0 clinical trials and 0 publications, and the evidence pack itself flags the prediction as a likely knowledge-graph false positive.

Quick Overview

Item	Content
Original Indication	Not confirmed in source data (`original_indications` empty; mechanistic rationale references thyroid eye disease as the known use)
Predicted New Indication	Monosomy X
TxGNN Prediction Score	99.79%
Evidence Level	L5 (model prediction only, no supporting studies)
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from DrugBank for this query (original_moa: [Data Gap]). Based on information embedded in the evidence pack's own rationale fields, teprotumumab is understood to act as an IGF-1R (insulin-like growth factor 1 receptor) antagonist, with established use in thyroid eye disease.

The top-ranked prediction, monosomy X, is the cytogenetic form of Turner syndrome. The evidence pack's own repurposing rationale flags a direction conflict: Turner syndrome is clinically managed with growth-hormone/IGF-1-axis therapies that promote growth in affected patients, whereas teprotumumab blocks IGF-1R signaling. Blocking the same axis that clinicians are trying to stimulate is mechanistically backwards, not complementary.

Compounding this, 6 of the 10 top-ranked predictions (ranks 1, 4, 6, 7, 8, 10) are all variants of the same Turner-syndrome/sex-chromosome-anomaly disease cluster, and 3 more (ranks 2, 3, 9) are all variants of a single venous/vascular disease cluster (esophageal varices, varicose disease). This pattern is consistent with TxGNN embedding proximity within disease-similarity clusters rather than 10 independent pharmacological hypotheses. With zero clinical trials and zero literature across all 10 candidates, none currently clears even a preliminary plausibility bar.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Teprotumumab currently holds no marketing authorization in Finland (0 licenses on file); no dosage forms or approved-indication text are available to tabulate.

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA package-insert warnings/contraindications for this drug are flagged in the evidence pack as a Blocking data gap — DG001 — pending PDF retrieval and parsing from the TFDA site.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top prediction (monosomy X) and all 9 runner-up candidates sit at Evidence Level L5 with zero clinical trials and zero literature support. The evidence pack's own mechanistic rationale identifies a direction conflict for the Turner-syndrome cluster (IGF-1R blockade vs. the growth-promoting therapy this population needs) and attributes the remaining candidates to graph-clustering artifacts rather than independent biological hypotheses.

To proceed, the following is needed:

TFDA package insert (warnings, contraindications) — currently a Blocking gap (DG001)
Confirmed original indication and MOA from DrugBank (currently Data Gap, DG002)
A mechanistically coherent hypothesis for any candidate indication, independently reviewed before further evidence-gathering is commissioned
Preclinical or case-level evidence for at least one candidate before advancing past S0
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.